Neuroscience Outside the Box: From the Laboratory to Discussing Drug Abuse at Schools

Imagem de Miniatura
Arquivos
art_VALE_Neuroscience_Outside_the_Box_From_the_Laboratory_to_2022.PDF (1.07 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
VALE, Thereza Cristina Machado do
CHAGAS, Luana da Silva
PEREIRA, Helena de Souza
GIESTAL-DE-ARAUJO, Elizabeth
BOMFIM, Priscilla Oliveira-Silva
Citação
FRONTIERS IN HUMAN NEUROSCIENCE, v.16, article ID 782205, 8p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
One of the effects of the current COVID-19 pandemic is that low-income countries were pushed further into extreme poverty, exacerbating social inequalities and increasing susceptibility to drug use/abuse in people of all ages. The risks of drug abuse may not be fully understood by all members of society, partly because of the taboo nature of the subject, and partly because of the considerable gap between scientific production/understanding and communication of such knowledge to the public at large. Drug use is a major challenge to social development and a leading cause of school dropout rates worldwide. Some public policies adopted in several countries in recent decades failed to prevent drug use, especially because they focused on imposing combative or coercive measures, investing little or nothing in education and prevention. Here we highlight the role of neuroscience education as a valid approach in drug use education and prevention. We propose building a bridge between schools and scientists by promoting information, student engagement and honest dialogue, and show evidence that public policy regulators should be persuaded to support such science-based education programs in their efforts to effect important positive changes in society.
Palavras-chave
neuroscience, education, public policies, science outreach, drug education
URI
https://observatorio.fm.usp.br/handle/OPI/48932
Referências
  1. Abreu-Villaca Y, 2003, NEUROPSYCHOPHARMACOL, V28, P1935, DOI 10.1038/sj.npp.1300221
  2. Arain M, 2013, NEUROPSYCH DIS TREAT, V9, P449, DOI 10.2147/NDT.S39776
  3. Australian curriculum review, 2021, HLTH PHYS ED
  4. Barbosa A., 2021, RES SOC DEVEL, V10, DOI [10.33448/rsd-v10i5.15097, DOI 10.33448/RSD-V10I5.15097]
  5. Bauman A, 1999, DRUG ALCOHOL DEPEN, V55, P187, DOI 10.1016/S0376-8716(99)00016-2
  6. Biederman J, 2000, PEDIATRICS, V106, P792, DOI 10.1542/peds.106.4.792
  7. Bittencourt Ana Luiza Portela, 2015, Rev. Bioét., V23, P311, DOI 10.1590/1983-80422015232070
  8. Bossong MG, 2013, EUR NEUROPSYCHOPHARM, V23, P1687, DOI 10.1016/j.euroneuro.2013.06.009
  9. BOTVIN GJ, 1992, J DEV BEHAV PEDIATR, V13, P290
  10. Brown SA, 2000, ALCOHOL CLIN EXP RES, V24, P164, DOI 10.1111/j.1530-0277.2000.tb04586.x
  11. Bruer JT, 1997, ED RES, V8, P4, DOI [10.3389/fpsyg.2016.00377, DOI 10.3389/FPSYG.2016.00377]
  12. Cardoso Luciana Roberta Donola, 2014, Psicol. Esc. Educ., V18, P27
  13. Carney T, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008969.pub3
  14. Chaffee BW, 2021, JAMA PEDIATR, V175, P715, DOI 10.1001/jamapediatrics.2021.0541
  15. Chagas LD, 2022, J BIOL EDUC, V56, P190, DOI 10.1080/00219266.2020.1757489
  16. Cheng MT, 2011, INT J SCI EDUC, V33, P299, DOI 10.1080/09500693.2010.482571
  17. Counotte DS, 2009, NEUROPSYCHOPHARMACOL, V34, P299, DOI 10.1038/npp.2008.96
  18. Cowie H, 2021, CHILD SOC, V35, P62, DOI 10.1111/chso.12430
  19. Cservenka A, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01111
  20. D'Souza DC, 2008, NEUROPSYCHOPHARMACOL, V33, P2505, DOI 10.1038/sj.npp.1301643
  21. Epstein J, 2016, J CHILD ADOLES SUBST, V25, P504, DOI 10.1080/1067828X.2015.1103348
  22. Ernst M, 2014, BRAIN COGNITION, V89, P104, DOI 10.1016/j.bandc.2014.01.006
  23. EU-OSHA,, 2017, SAF HLTH MICR SMALL
  24. Faggiano F, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003020.pub2
  25. Faggiano F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003020.pub3
  26. Faggiano F, 2010, DRUG ALCOHOL DEPEN, V108, P56, DOI 10.1016/j.drugalcdep.2009.11.018
  27. Fischhoff B, 2013, P NATL ACAD SCI USA, V110, P14033, DOI 10.1073/pnas.1213273110
  28. FLAY BR, 1994, J HEALTH SOC BEHAV, V35, P248, DOI 10.2307/2137279
  29. Fletcher A, 2008, J ADOLESCENT HEALTH, V42, P209, DOI 10.1016/j.jadohealth.2007.09.020
  30. Forster M, 2018, ADDICT BEHAV, V76, P298, DOI 10.1016/j.addbeh.2017.08.037
  31. Fowler Joanna S, 2007, Sci Pract Perspect, V3, P4
  32. Fuhrmann D, 2015, TRENDS COGN SCI, V19, P558, DOI 10.1016/j.tics.2015.07.008
  33. Galvao A., 2017, REV PORTUG ENFERM SA, V5, P8, DOI [10.19131/rpesm.0160, DOI 10.19131/RPESM.0160]
  34. Gilligan C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012287.pub2
  35. Glei DA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226732
  36. Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101
  37. Gould TJ, 2014, NEUROBIOL LEARN MEM, V107, P108, DOI 10.1016/j.nlm.2013.08.004
  38. Henkel Dieter, 2011, Curr Drug Abuse Rev, V4, P4
  39. Hill KG, 2005, J ADOLESCENT HEALTH, V37, P202, DOI 10.1016/j.jadohealth.2004.08.014
  40. Horvath JC, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00377
  41. Howard-Jones PA, 2012, NEUROETHICS-NETH, V5, P119, DOI 10.1007/s12152-011-9101-0
  42. Kapitany-Foveny Mate, 2018, JMIR Serious Games, V6, pe19, DOI 10.2196/games.9944
  43. Kim MJ, 2009, PEDIATRICS, V124, P895, DOI 10.1542/peds.2008-2015
  44. Kim YH, 2017, CHILD ABUSE NEGLECT, V67, P338, DOI 10.1016/j.chiabu.2017.03.009
  45. Klisch Y, 2013, J DRUG EDUC, V43, P255, DOI 10.2190/DE.43.3.d
  46. Laranjeira R., 2012, RONALDO LARANJEIRA S
  47. Lemgruber J., 2021, TIRO IMPACTOS PROIB
  48. LeNoue SR, 2016, CHILD ADOL PSYCH CL, V25, P297, DOI 10.1016/j.chc.2015.11.007
  49. Leslie FM, 2020, PHARMACOL BIOCHEM BE, V197, DOI 10.1016/j.pbb.2020.173010
  50. Lichtenberg NT, 2020, MIND BRAIN EDUC, V14, P387, DOI 10.1111/mbe.12261
  51. Lilienfeld S.O., 2014, SCIENTIF AM MIND, V25, P70, DOI [10.1038/scientificamericanmind0114-70, DOI 10.1038/SCIENTIFICAMERICANMIND0114-70]
  52. MacArthur G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009927.pub2
  53. Marquez MC, 2020, FRONT COMMUN, V5, DOI 10.3389/fcomm.2020.00031
  54. Mays D, 2014, PEDIATRICS, V133, P983, DOI 10.1542/peds.2013-3003
  55. McHugh RK, 2019, ALCOHOL RES-CURR REV, V40, P3, DOI 10.35946/arcr.v40.1.01
  56. Meier MH, 2012, P NATL ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109
  57. Miller Leslie, 2006, CBE Life Sci Educ, V5, P137, DOI 10.1187/cbe.05-08-0115
  58. Mills J, 2020, AM FAM PHYSICIAN, V102, P493
  59. Olfson M, 2018, JAMA PSYCHIAT, V75, P820, DOI 10.1001/jamapsychiatry.2018.1471
  60. Owens MM, 2019, NEUROPSYCHOPHARMACOL, V44, P613, DOI 10.1038/s41386-018-0240-4
  61. Pan W, 2009, INT J ENV RES PUB HE, V6, P267, DOI 10.3390/ijerph6010267
  62. Petker T, 2019, J PSYCHIATR NEUROSCI, V44, P414, DOI 10.1503/jpn.180115
  63. Ramaekers JG, 2009, J PSYCHOPHARMACOL, V23, P266, DOI 10.1177/0269881108092393
  64. Rehan W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177252
  65. Roche J, 2020, FRONT SOCIOL, V5, DOI 10.3389/fsoc.2020.613814
  66. Ryan SM, 2010, AUST NZ J PSYCHIAT, V44, P774, DOI 10.1080/00048674.2010.501759
  67. Sanchez ZM, 2021, INT J DRUG POLICY, V98, DOI 10.1016/j.drugpo.2021.103413
  68. Secades-Villa R, 2015, INT J DRUG POLICY, V26, P135, DOI 10.1016/j.drugpo.2014.07.011
  69. Shek DTL, 2020, J PSYCHOACTIVE DRUGS, V52, P66, DOI 10.1080/02791072.2019.1707333
  70. Sigman M, 2014, NAT NEUROSCI, V17, P497, DOI 10.1038/nn.3672
  71. Silva RB, 2017, EDUC ESCRITO, V8, P35, DOI 10.15448/2179-8435.2017.1.24527
  72. Silva M. da C. A., 2016, SMAD. Revista Eletronica Saude Mental Alcool e Drogas, V12, P30, DOI 10.11606/issn.1806-6976.v12i1p30-39
  73. Smit K, 2018, CLIN PSYCHOL REV, V60, P136, DOI 10.1016/j.cpr.2018.02.002
  74. Squeglia LM, 2015, AM J PSYCHIAT, V172, P531, DOI 10.1176/appi.ajp.2015.14101249
  75. Squeglia LM, 2012, J STUD ALCOHOL DRUGS, V73, P749, DOI 10.15288/jsad.2012.73.749
  76. Stapinski LA, 2018, DRUG ALCOHOL REV, V37, pS420, DOI 10.1111/dar.12611
  77. Tapert Susan F, 2005, Recent Dev Alcohol, V17, P177, DOI 10.1007/0-306-48626-1_9
  78. Theunissen EL, 2012, PSYCHOPHARMACOLOGY, V220, P341, DOI 10.1007/s00213-011-2479-x
  79. Tice P., 2017, SUSTANCE 12 GRADE AG
  80. Tyng CM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01454
  81. United Nations Office on Drugs and Crime (UNODC), 2021, WORLD DRUG REPORT 20
  82. US Department of Health and Human Services,, 2016, E CIG US YOUTH YOUNG
  83. Valentine G, 2018, CURR NEUROPHARMACOL, V16, P403, DOI 10.2174/1570159X15666171103152136
  84. Valkov P., 2018, TRAKIA J SCI, V16, P95, DOI [DOI 10.15547/tjs.2018.02.004, 10.15547/tjs.2018.02.004]
  85. Vasters GP, 2011, REV LAT-AM ENFERM, V19, P317, DOI 10.1590/S0104-11692011000200013
  86. Willoughby T, 2013, BRAIN COGNITION, V83, P315, DOI 10.1016/j.bandc.2013.09.008
  87. World Health Organization, 2016, DRUG US ROAD SAF POL
  88. World Health Organization, 2004, NEUR PSYCH SUBST US
  89. World Health Organization [WHO], 2014, HLTH WORLDS AD 2 CHA
  90. Zarrindast MR, 2019, BRAIN RES, V1710, P92, DOI 10.1016/j.brainres.2018.12.002

Coleções
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - ODS/01
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/04
Artigos e Materiais de Revistas Científicas - ODS/10